Saturday 17 October 2026
Export CLPT’s income statement to Excel — free account
ClearPoint Neuro, Inc.
CLPT Healthcare Medical Devices
ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
9.07
0.57
−5.91%
Follow CLPT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.73 | 6.62 | 10.48 | 18.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(76.72) | (33.75) | (32.07) | (198.47) | |
P/B ratio |
49.94 | 14.27 | 13.82 | 39.02 | |
Price to Tangible BV |
0.00 | 0.00 | 58.46 | 39.29 | |
EV/Sales |
13.22 | 6.97 | 10.56 | 17.78 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.52) | (11.00) | (16.33) | (46.65) | |
EV/FCF |
(17.56) | (10.38) | (15.63) | (42.47) | |
Quick Ratio |
3.66 | 4.67 | 4.87 | 5.24 | |
Current Ratio |
4.74 | 5.79 | 5.91 | 6.37 | |
Net Debt/EBITDA |
(2.37) | (1.92) | (0.51) | 1.87 | |
Debt/Assets |
57.91% | 53.14% | 50.21% | 48.38% | |
Debt/Equity |
4.66 | 2.63 | 1.75 | 1.84 | |
Asset Turnover |
0.57 | 0.66 | 0.54 | 0.68 | |
Operating CF/Net income |
0.62 | 0.83 | 1.55 | 0.53 | |
Capex/Depreciation |
(0.15) | (0.56) | (0.06) | (0.43) | |
Interest Coverage |
(7.25) | (6.13) | (3.48) | — | |
Research and Development Expense of Revenue |
42.57% | 37.29% | 31.10% | 38.96% | |
Selling, General and Administrative Expense of Revenue |
113.25% | 96.57% | 98.10% | 83.78% | |
Intangible Assets out of Total Assets |
0.24 | 0.22 | 0.22 | 0.00 | |
Share Based Compensation of Revenue |
20.87% | 18.29% | 19.03% | 22.82% | |
Graham Net Nets |
(0.05) | (0.07) | (0.02) | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.61%) | (11.10%) | (6.65%) | (3.85%) | |
Free Cash Flow Yield |
(5.92%) | (10.14%) | (6.45%) | (2.32%) | |
Revenue per Share |
0.36 | 0.41 | 0.37 | 0.31 | |
Operating CF per Share |
(0.23) | (0.27) | (0.43) | (0.11) | |
Capex per Share |
(0.01) | (0.02) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.24) | (0.29) | (0.43) | (0.12) | |
Cash per Share |
0.97 | 1.20 | 1.62 | 1.34 | |
Shareholders Equity per Share |
0.36 | 0.64 | 0.99 | 0.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.64 | 0.99 | 0.56 | |
Free Cash Flow |
(7.23) | (8.61) | (12.13) | (3.32) | |
Working Capital |
38.62 | 45.40 | 52.84 | 43.28 | |
Capital Expenditures |
(0.21) | (0.64) | (0.05) | (0.20) | |
Net Current Asset Value |
(27.03) | (19.70) | (6.13) | 6.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.05 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.33 | 6.16 | 5.63 | 3.94 | |
Average Payables |
1.84 | 1.77 | 1.30 | 0.84 | |
Average Inventory |
7.55 | 7.58 | 7.61 | 6.82 | |
Average Assets |
74.81 | 61.74 | 68.47 | 50.28 | |
Average Common Equity |
15.26 | 19.41 | 26.70 | 22.44 |
Columns are period end dates